KR20220010415A - Oil composition containing unsaturated fatty acid in a certain content and use thereof - Google Patents

Abstract

The present invention relates to an oil-fat composition containing unsaturated fatty acids (HUFA) such as DHA, EPA, ARA, and DHA. compositions and pharmaceutical compositions. The fish oil composition or oil-fat composition according to the present invention is intended to provide a functional food that helps prevent anti-inflammatory, anti-viral, immune enhancement, or cognitive improvement (dementia).

Description

Oil composition containing unsaturated fatty acid in a specific content and use thereof

The present invention relates to an oil-fat composition comprising unsaturated fatty acids in a specific content and uses thereof, and specifically, to a fat-and-fat composition comprising highly unsaturated fatty acids (HUFA) such as DHA, EPA, and ARA in a specific content, and the It relates to various uses of the composition.

As a currently announced functional material, only Omega-3 composed of EPA and DHA is beneficial to eye health if the total daily intake of the two components is 0.9-2g, regardless of the composition ratio of the two components, either high in EPA or high in DHA. It is licensed and sold as a health functional food that helps improve brain function and cognition, and improves blood clots and blood flow.

However, all omega-3 products so far are concentrated products after refining or esterifying fish oil from various fish such as salmon, sardine, herring, anchovies, krill, and seahorse. Although EPA is slightly different depending on the fish species, it contains 1.5 times more EPA than functional DHA, and the two substances are expensive to separate and purify by molecular distillation, so it is difficult to scientifically reconstruct the ratio of EPA and DHA in the components. is difficult This is because fish oil contains extremely low amounts of ARA (abbreviated as AA in the literature) and DPA than EPA and DHA. Also, unlike humans, most fish do not have the physiological function of procuring energy from carbohydrate metabolism, and are animals that obtain almost all energy from fat metabolism. It was thought to be caused by a lack of research on

Existing EPA and DHA are simply refined oil extracted from various fish such as salmon, herring, anchovies, and sardines, called refined oil or TG (triglyceride), and usually EPA 18-19% DHA 11-13% EPA and DHA total about 30% EPA/DHA ratio of 1.56 (DHA/EPA ratio 0.6), esterified by adding ethanol (Ethanol) to fish oil or these fish oil companies, and then concentrated is called EE type and EPA 19.4-51.1% DHA 12,4-25.7% EPA/DHA ratio 1.56 (DHA/EPA ratio 0.64) 30-50% of EPA and DHA in total, or EE-type re-mixed with triglyceride is supplied as rTG. eh, health functional food companies purchase fish oil containing unsaturated fatty acids such as EPA and DHA, respectively, and then fill soft capsules with 0.5-2 g in various sizes and sell them. In addition, as a result of analyzing the EPA/DHA ratio of 20 types of omega-3 production fish oil imported into Korea (10 types of TG type and 10 types of EE type) imported into Korea, 19 types were about 1.5, and it was found that there were 0.96 types in 1 type. In addition, governments in each country do not distinguish between TG type, EE type, and rTG type, and when converted as EPA and DHA, the total dose of EPA and DHA is 0.5-2 g per day, which helps eye health such as dry eye syndrome, improves brain cognition, cholesterol It has been approved as having the functions of removal and blood flow improvement, and the Ministry of Food and Drug Safety in Korea announces clear and detailed standards for specific details.

However, the human brain is dry matter, and about 60% of it is fat, of which 20% is DHA, and the bloodstream contains more EPA than DHA. EPA has been announced to have a blood flow improvement function by decomposing blood clots, and there is a health functional food reevaluation report saying that taking more than 3g of DHA and EPA per day may cause side effects such as poor hemostasis.

Within the permitted amount, there are no side effects from DHA, and for EPA, there is a lack of reliable information on the safety of intake by pregnant and lactating women. Concomitant administration with enoxaparin, heparin, warfarin, etc.) may increase the risk of bleeding, so caution should be exercised when administering concomitantly. is included.

These side effects also require a greater amount of DHA than EPA for human physiological functions. Instead of reconstituting the composition ratio of fish oil, which has completely different physiological functions from humans, to suit the human body, it is simply purified, concentrated, and esterified to improve absorption. Because the product was made. Therefore, there is a growing need to develop a product designed to suit the physiological functions of humans in the mixing ratio of DHA and EPA.

The Korean Journal of Lipid and Arteriosclerosis, Volume 13, No. 2 states that normal mother's blood contains EPA 2.72 ± 0.96 DHA 3.10 ± 0.58 and DHA/EPA Ratio of 1.14, and cord blood, the source of life, contains EPA 1.65 ± 0.64 , DHA 3.43 ± 0.52, with a DHA/EPA ratio of 2.08. In other words, the ratio of DHA:EPA in cord blood, which is the mystery of the birth of life, to maternal blood during pregnancy is 2 : 1, which is the same as the composition ratio of antiviral effect when producing fish seedlings. found the same thing.

In addition, the present inventors focused on the fish life-born food chain, and among marine microalgae consumed by rotifers, the initial food of fish Larvae, species containing a lot of DHA, EPA, ARA, and DPA, respectively. After selecting and culturing (species), DHA, EPA, ARA, and DPA are isolated and extracted, and the composition ratio is within 2 g of daily intake. Preferably, it is formulated to contain 2.0 times or more, and by adding omega-6 ARA and omega-5 DPA, the existing efficacy and effect of omega-3 is improved, and there are almost no side effects due to EPA, and antiviral and inflammatory This invention was completed by discovering that there is a new effect for prevention, improvement or treatment, immunity enhancement, and dementia prevention.

Laid-Open Patent Publication No. 10-2016-0025015

Journal of the Korean Society for Food and Nutrition Korean J. food & Nutri. Vol 26 No 3 352 - 357 (2013)

The present invention provides a composition and pharmaceutical composition of a health functional food that is recognized for its efficacy in improving eye health, brain cognition, and blood flow, such as the heart, when 0.5-2 g per day is ingested as a total weight of EPA and DHA called omega-3 fatty acids. would like to provide

In the present invention, the ratio of DHA/EPA to the original fish oil is 0.6, which is the most suitable ratio for the hatching of fish eggs and the formation and growth of embryonic stem cells by division and proliferation. When the ratio of DHA/EPA is more than 2.0 when the ratio of DHA/EPA is higher than the ratio of 0.6, the antiviral action and resistance to bacterial attack are strong. .

In other words, after hatching a flatfish egg, the hatched fish moves the nutrients in the oil sac (oil bag) that are released during hatching as energy for 3 days after hatching. After consuming rotifers (protozoa) for about 20 days, they eat Artemia nauplii (copeptides) for about 1-3 weeks and then eat compound feed to grow into fry. However, rotifer and Artemia nauplii lack DHA, EPA, ARA, and DPA. Ratio 0.6) is dispersed and adsorbed in the emulsified form or during cultivation in Chlorella they eat, so that Rotifer and Artemia can eat it. If you produce fry while doing it, fry production is done without any problem.

However, water or egg-derived Herpes Virus, Birna Virus, Nervous Necrosis Virus, RhaBdovirus, Vibrio ichthyoenteri, Vibrio alginolitis In the presence of pathogenic viruses and bacteria such as Vibrio alginolyticus and Vibrio harveyi, annihilation or significant loss of hair occurs.

However, rotifer and Artemia nauplii are not fortified with fish oil-derived omega-3 (EPA, DHA, ARA, DPA), but with DHA, EPA, and ARA extracted from microalgae. As a result of nutritional enhancement while adjusting the ratio by trial and error, the DHA/EPA ratio is 2.0 or higher EPA/ARA ratio 2.0 or higher DPA is the fish oil composition ratio. found out that

Microalgae from which the unsaturated fatty acids can be extracted include Schizochytrium sp, Nanochloropsis oculata , Isochrysis galbana , Tetraselmis suecica ), and it may include two throwing away Ella Salina (Dunaliella salina), two flying it Ella Terre thio rekta (Dunaliella tertiolecta), species Pavlova (Pavlova sp) is suggested (Lobosphaera incisa), Robo Spanish La or the like.

DHA, EPA, ARA, and DPA are extracted from these microalgae, and the ratio of DHA, EPA, ARA, and DPA in these microalgae is replaced with chlorella without fortifying nutrition. Powder or powder or If Rotifer and Artemia nople fed with algal culture are fed to flatfish and raised, they have strong disease resistance against various pathogenic viruses and bacteria.

In order to achieve the above object, the present invention is to provide a fish oil composition or oil composition comprising an unsaturated fatty acid in a specific mixing ratio or content.

In addition, it is intended to provide a pharmaceutical composition or a food composition comprising the fish oil composition or oil composition.

Oil in the present invention is a concept including any one or more of fat (Fat), oil (Oil), fatty acid (Fatty acid).

The unsaturated fatty acid contained in the composition is not limited, but preferably at least one of DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), ARA (arachidonic acid), DPA (docosapentaenoic acid) It may include, and more preferably, may include any one or more of DHA, EPA, and ARA.

The unsaturated fatty acids contained in the oil-fat composition according to the present invention may be obtained from animal oil and/or non-animal oil, mold, and the like.

In some embodiments of the present invention, the fatty acid oil mixture may be obtained from at least one oil selected from marine life oil, marine microalgal oil, plant oil, and microbial oil.

Marine life oils include, for example, fish oil, krill oil, and oil-fat compositions obtained from fish.

Marine microalgae oil can be obtained from marine microalgae such as Diatom, Blue-green algae and Green-algae.

Specifically, diatoms are Bacillariophyceae, Eunotiophycidae, Fragilariophycidae, Biddulphiophycidae, Chaetocerotophycidae, Cymatosirophycidae, and Cymatosirophycidae. It may be derived from marine microalgae included in the genus Thalassiosirophycidae, but is not limited thereto.

Blue-green algae are marine microalgae included in genera such as Gloeobacterales, Chroococcales, Pleurocapsales, Nostocales and Stigonematales. may be derived, but is not limited thereto.

Green algae is seukijo kit Solarium (Schizochytrium), nano claw drop system (Nannochloropsis), isopropyl Cri sheath (Isochrysis), tetra-cell Miss (Tetraselmis), two flying it Ella (Dunaliella), Pavlova (Pavlova), and Lobo Spanish La (Lobosphaera) It may be derived from marine microalgae included in the genus, but is not limited thereto.

Plant-based oils also include, for example, flaxseed oil, carola oil, mustard seed oil, and soybean oil.

The microbial oil may be, for example, a product of Martek, but is not limited thereto.

In some embodiments of the present invention, fatty acids such as omega-3 fatty acids of the fatty acid oil mixture are esterified as alkyl esters, such as ethyl esters. In some embodiments, the fatty acid may be selected from mono-, di-, and triglycerides.

In some embodiments, the fatty acid oil mixture is a physico-chemical purification comprising transesterification of anchovy oil or oily fish body oil derived from tuna oil, and urea fractionation and molecular distillation. obtained by the process. In some embodiments, the crude oil mixture may be subjected to a stripping process to reduce the amount of environmental contaminants and/or cholesterol prior to transesterification.

In another embodiment, the fatty acid oil mixture is obtained using supercritical CO ₂ extraction or chromatography techniques, eg, high-concentration of primary EPA and DHA in a fish oil concentrate.

The oil-fat composition of the present invention may include at least one other fatty acid in addition to the unsaturated fatty acid. Examples of such fatty acids include, but are not limited to, omega-3 fatty acids and omega-6 fatty acids other than EPA and DHA. For example, in some embodiments of the present invention, the fatty acid oil mixture is α-linolenic acid (ALA), henicosapentaenoic acid (HPA), docosapentaenoic acid (DPA), eicosatetraenoic acid ( ETA), eicosatrienoic acid (ETE), stearidonic acid (STA) and at least one fatty acid other than EPA and DHA. In some embodiments, the at least one fatty acid other than EPA and DHA is selected from linolenic acid, gamma-linolenic acid (GLA), arachidonic acid (AA), docosapentaenoic acid (ie osbond acid), and mixtures thereof. In some embodiments, the at least one fatty acid other than EPA and DHA may be selected from ethyl esters and triglycerides.

When DHA and EPA are mixed among the unsaturated fatty acids, the ratio of DHA/EPA may be 0.1 or more. Specifically, the ratio of DHA / EPA may be included in a ratio of 0.1 to 20, preferably 0.1 to 10.

In one embodiment of the present invention, the ratio of DHA / EPA may be included in a ratio of 0.1 to 10, preferably 0.1 to 5, preferably 1 to 3, more preferably 1.4 to 2.9, but is not limited thereto. . The ratio may be a volume ratio, a weight ratio, a molar ratio, or the like, but preferably a weight ratio.

The ratio of DHA / EPA as described above, regardless of whether the fish oil-derived TG type, EE type, or rTG type, DHA extracted from Schizochytrium sp. After ethyl esterification of DHA in EE type, it can be formulated to match the composition ratio.

In addition, ARA in addition to DHA and EPA among the unsaturated fatty acids may be further included. In this case, the ARA may be an EPA/ARA ratio of 0.1 or more.

Specifically, the ratio of EPA / ARA may be included in a ratio of 0.1 to 50, preferably 1 to 30, more preferably 1 to 10, but is not limited thereto.

The unsaturated fatty acid may be included in an amount of 5 to 65% by weight, preferably 10 to 55% by weight, more preferably 15 to 50% by weight relative to the total weight of the oil composition.

The unsaturated fatty acid may also be included in 30 wt% or more, preferably 40 wt% or more, more preferably 50 wt% or more, based on the total weight of the composition. In one embodiment of the present invention, it may be included in an amount of 50% by weight, but is not limited thereto.

The composition is not limited, but preferably may be provided as a composition for enhancing immunity, preventing, improving or treating inflammation, antiviral or dementia prevention.

In the present invention, the inflammation is IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-12/23p40, IL-15/15R , by inflammatory factors such as IL-17A, IL-21, IL-22, IL-23 (IL-12p40/IL-23p19), IL-33, TNF-alpha, IFN alpha, IFN beta, IFN gamma, prostaglandins it will happen

Accordingly, the composition according to the present invention can prevent, improve or treat inflammation by reducing the amount of the above factors.

The oil-fat composition according to the present invention may be provided as any one composition of a pharmaceutical composition or a food composition.

The pharmaceutical composition may be prepared in the form of a self-known formulated composition or soft capsule, preferably enclosed in a soft gelatin capsule, using a conventionally known method in formulation, but is not limited thereto. In addition, it may further include a pharmaceutically acceptable carrier, additives and auxiliary materials.

The food composition may further include flavoring agents, flavoring agents, stabilizers, thickeners, preservatives, etc. commonly used in the art for preparing food, for example, lactose, dextrose, sucrose, Sorbitol, mannitol, xylitol, erythritol, malditol, starch, alginate, calcium phosphate, calcium silicate, maltodextrin, silicon dioxide, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, methylhydroxybenzoate, propyl hydride It may be oxybenzoate, talc, magnesium stearate, etc., but is not limited thereto.

In addition, the food composition may be prepared in the form of beverages, gums, tea, vitamin complexes, powders, granules, tablets, capsules, confectionery, and the like.

The food composition according to the present invention may be appropriately selected according to the age, weight, health status, sex, administration time, content of active ingredient, severity of disease, etc. of the ingestion target, and the number of intakes is once or twice a day, It can be taken every other day, every other week, every other month, etc.

The pharmaceutical composition may further include pharmaceutically acceptable excipients, carriers, disintegrants, binders, lubricants, binders, fragrances, and the like, in addition to polysaccharides.

The pharmaceutical composition may be prepared in the form of tablets, capsules, sustained-release preparations, elixirs, suspensions, syrups, wafers, unit dose injection ampoules, suspensions, etc. by methods commonly used for formulation in the art.

The administration method of the pharmaceutical composition is oral administration, intravenous administration, intramuscular administration, intraarterial administration, intramedullary administration, intrathecal administration, intracardiac administration, transdermal administration, subcutaneous administration, intraperitoneal administration, intranasal administration, enteral administration It may be administered by methods such as topical administration, rectal administration, topical administration, dermal administration, mucosal administration, intravertebral administration, etc., including oral and sublingual administration, and preferably oral administration, but is not limited thereto. In addition, at the time of administration, it may be formulated and administered in a formulation appropriate for each administration method, and the formulation may be formulated by a method widely known in the art.

The pharmaceutical composition may be appropriately selected according to several factors including the age, weight, health status, sex, administration time, administration route, excretion rate, drug formulation, and severity of a specific disease to be prevented or treated of the subject to be administered, and the number of administration may be administered once or twice a day, every other day, every other week, every other month, or the like.

The method of configuring the oil composition of microalgae extracted DHA, EPA, and ARA according to the present invention can be variously configured with reference to Table 1 below for the composition of DHA, EPA and ARA for each microalgae, so the means of solving the problem is microalgae Using the extracted fats and oils, it is possible to provide a fat and oil composition containing unsaturated fatty acids in various mixing ratios in various ways.

Microalgae name % of total fat content per dry weight DHA % of total fat % EPA of total fat ARA % of total fat Schizochytrium 65 20 0.25 Nanochloropsis 18 0.3 28.7 2.7 Tetraselmis 11 ND 5.4 1.1 Pavlova 20 6.2 22.0 0.9 Isochrysis 19 11.2 1.2 0.4 Lobosphaera
( Lobosphaera incisa ) 19.4 ND 2.3 15.3

Tuna Head Oil may be used to provide the oil composition according to the present invention. Tuna head oil contains a lot of DHA with 15.7-17.3% of total fat, so 25.5% of DHA products are sold. With this, you can adjust the ratio of the existing omega-3 products to the DHA/EPA composition to be 1.0 or higher. However, when using tuna oil, only those that do not contain mercury (Hg) should be selected and used.

Omega-3 products are not only manufactured in the form of convenient soft capsules using oil, but also can be manufactured with the dried product itself without squeezing the oil by drying marine microalgae.

The present invention is a DHA/EPA of fish oil-derived unsaturated fatty acids (HUFA) that manufactures omega-3 products without scientifically identifying the physiological and metabolic functions of each of DHA and EPA in the existing omega-3 (DHA + EPA) product. The ratio of 0.6 (ratio of EPA/DHA to 1.5) is high to separate, purify and reconstitute even with modern scientific technologies such as molecular distillation method. The total dose of DHA, EPA, and ARA is determined to be different from the required amount of DHA, EPA, and ARA, which can maximize the efficacy and effect of human physiology by determining the daily intake to less than 2 g. In other words, if 2g of DHA and EPA is ingested per day, EPA may be ingested in excess, resulting in poor hemostasis due to increased thrombolytic action or adverse effects such as decreased anti-inflammatory function. Due to the low activation of ability function, dementia prevention function and antiviral function were not recognized. However, according to the present invention, the composition ratio of DHA and EPA is opposite to that of the existing Oega-3 product while taking the same dose as the total of DHA and EPA, preferably 1.1 or more, and most preferably 2.0 or more. While maintaining or improving the three recognized functions of omega-3, antiviral, immune enhancement, prevention, improvement or treatment of inflammation, and dementia prevention functions are added, which is thought to greatly contribute to the healthy life of mankind.

In addition, by adding the EPA/ARA mixing ratio to be 2.0 or higher, the antiviral effect, immunity enhancement, prevention, improvement or treatment effect of inflammation, and the prevention effect of dementia are further strengthened. It is expected that the enhancement of the human body's own immunity in the environment will greatly contribute to an essential healthy diet, not an option.

Hereinafter, the present invention will be described in detail with reference to Preparation Examples, Examples and Experimental Examples.

However, the following Preparation Examples, Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples and Experimental Examples.

<Preliminary Experimental Example 1> Analysis of unsaturated fatty acids contained in microalgae and fish oil

In order to evaluate the type and content of unsaturated fatty acids contained in microalgae or fish oil, the experiment was conducted as follows, and the results are shown in Table 2.

1) Preparation of Analytical Sample Solution:

Put 250 mg of fatty acid oil in a 25 mL volumetric flask, dissolve it with hexane and adjust the volume. Add 0.2 mL of 4M (mol/L) MeOH solution to 2 mL of this solution, vibrate for 1 minute ultrasonically, and store for 10 minutes.

2) Analysis conditions

Column DB-5ms ( 60.0 m × 0.25 mm × 0.25 μm) Temp. After holding at 100°C for 3 minutes, increase to 260°C at 10°C/min, and then hold for 8 minutes carrier gas nitrogen flow velocity 1.0mL/min Inlet temp. 250℃

As a result of the evaluation, algae showed a high total fat content per dry matter weight, but the content of specific unsaturated fatty acids was different. In Isochrysis , the DHA content was relatively high, and in Lobosphaera, the ARA content was relatively high. Nanoclopsis (Nannochloropsis) and Pavlova ( Pavlova ) showed the highest content of EPA, Schizochytrium ( Schizochytrium ) In DHA, tetraselmis ( Tetraselmis ) EPA content was high.

DHA and EPA were high in fish oil and tuna head oil, but ARA was not included.

target material % of total fat content per dry weight DHA % of total fat % EPA of total fat ARA % of total fat Isochrysis 1 19 11.2 1.2 0.4 Isochrysis 2 30 1.2 Lobosphaera 19.4 0.3 2.3 15.3 Nanochloropsis 18 28.7 2.7 Pavlova 20 6.2 22 0.9 Schizochytrium 1 65 20 0.25 Schizochytrium 2 40 Tetraselmis 11 0 5.4 1.1 fish oil 20 30 tuna head oil 25.5 4.8

<Preparation Examples 1 to 8>

Based on the results in Preliminary Experimental Example 1, an oil-fat composition was prepared according to the mixing ratio of Table 4 below so that unsaturated fatty acids could be uniformly included.

target material Preparation Example 1 Preparation Example 2 Preparation 3 Preparation 4 Production Example 5 Preparation 6 Preparation 7 Preparation 8 Isochrysis 1 40 Isochrysis 2 60 Lobosphaera 8 10 Nanochloropsis 25 37 30 Pavlova 25 Schizochytrium 2 20 50 76 55 Tetraselmis fish oil 75 100 80 50 24 tuna head oil 35

<Examples 1 to 8>

A fat composition according to the present invention was prepared, and the mixing ratio of unsaturated fatty acids is shown in Table 5.

sample mixing ratio DHA EPA ARA DHA/EPA EPA/ARA weight ratio Example 1 15.0 29.7 0.7 0.5 44.0 1: 2: 0.04 Example 2 20.0 30.0 - 0.7 0.7 : 1 Example 3 24.0 24.0 1.0 1:1 Example 4 30.0 15.0 2.0 2:1 Example 5 35.2 7.2 - 4.9 4.9:1 Example 6 22.0 10.8 2.2 2.0 4.9 2 : 1 : 0.21 Example 7 18.0 8.8 3.1 2.0 2.9 2 : 1 : 0.35 Example 8 15.0 7.7 0.4 2.0 19.9 2: 1: 0.05

<Experimental Example 1> Immune enhancing effect evaluation

In order to evaluate the immune enhancing effect of the oil composition according to the present invention, the experiment was conducted as follows.

The proliferative capacity of splenocytes was measured using immune cells isolated from mouse spleen. The experimental group was diluted to 1/800, 1/400, and 1/200 concentrations using Examples 1, 4, and 6, respectively, and treated. The comparative example was treated with LPS 10 μg/ml, the control group was treated with 5 μg/ml Concavaline A (Con A), and the results are shown in Table 6 below.

As a result of the experiment, in the order of Example 6> Example 4> Example 1, the DHA composition and ratio adjustment in the immune enhancing effect confirmed an excellent increasing effect for each untreated group and concentration. In Examples 6 and 4 in which ARA is additionally included, it can be seen that the immune enhancing effect is maintained even when diluted to a concentration of 1/800.

target sample Example 1 Example 4 Example 6 untreated group 100 100 100 1/800 dilution 76.92± 0.66 125.38± 3.72 147.30± 6.54 1/400 dilution 89.63± 3.13 143.63± 6.95 152.43± 3.12 1/200 dilution 90.38± 3.83 146.08±11.66 152.44±10.90 Control (5 ug/ml) 155.67± 7.56 155.67± 7.56 155.67± 7.56 Comparative Example (LPS 10 ug/ml) 176.73± 3.16 176.73± 3.16 176.73± 3.16

<Experimental Example 2> Anti-inflammatory effect evaluation

Since the anti-inflammatory effect also affects the immune enhancing effect, the experiment was conducted as follows to evaluate the anti-inflammatory effect of the oil composition according to the present invention.

The experimental method was conducted to evaluate the degree of inhibition of inflammatory factors induced in excess by LPS as a stimulant in mouse macrophages, and Examples 1 to 3 were treated with 0.01 and 0.02%, respectively. In the evaluation of inflammatory factor inhibition, IL-1 beta, IL-6, PGE2 (Prostaglandin E2) and NO production amount inhibition were selected as items, and the results are shown in Table 7.

target sample Anti-inflammatory evaluation items Sample control NO suppression IL-1β IL-6 PGE2 Comparative Example (Irritant) 100 100 100 100 Example 1 0.01 75.2 98.4 106.9 95.9 0.02 60 91 110.5 95.6 Example 4 0.01 34.5 49.6 69 61.7 0.02 27.2 40 68.2 58.3 Example 6 0.01 43.4 71.3 73.8 65.2 0.02 27.3 49.2 66.9 54.6

As a result of the experiment, except for the inhibitory effect of IL-6 of Example 1, it was found that the inflammatory factor inhibitory effect was excellent in Examples 1, 4, and 6 as a whole. In particular, when analyzing the anti-inflammatory effect in Examples 4 and 6 rather than Example 1, it is determined that the effect of DHA composition and ratio adjustment on the anti-inflammatory factor suppression is large as a result similar to the immune-enhancing effect.

Claims (7)

Oil composition comprising DHA / EPA in a weight ratio of 0.1 to 5. The oil-fat composition according to claim 1, wherein the composition contains DHA/EPA in a weight ratio of 1 to 3. The oil-fat composition according to claim 1, wherein the composition further comprises ARA, wherein the ratio of EPA/ARA is 0.1 to 30 by weight. The oil-fat composition according to claim 3, wherein the composition contains an EPA/ARA ratio of 0.1 to 10 by weight. The oil composition according to claim 1, wherein the DHA and EPA are included in an amount of 5 to 65% by weight of the total weight of the oil composition. A food composition for improving immunity, preventing or improving inflammation, comprising the composition of any one of claims 1 to 5. [Claim 6] A pharmaceutical composition for improving immunity, preventing, improving or treating inflammation, comprising the composition of any one of claims 1 to 5.